RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EKF Diagnostics Holdings Stock

EKF Diagnostics Holdings ROE 2024

EKF Diagnostics Holdings ROE

0.04

Ticker

EKF.L

ISIN

GB0031509804

WKN

622434

In 2024, EKF Diagnostics Holdings's return on equity (ROE) was 0.04, a -125.45% increase from the -0.14 ROE in the previous year.

EKF Diagnostics Holdings Aktienanalyse

What does EKF Diagnostics Holdings do?

EKF Diagnostics Holdings PLC is a service business that offers a wide portfolio of diagnostics, medical devices, and point-of-care systems. It is an international company that sells its products in more than 100 countries worldwide. The company has offices in North America, Europe, and Asia-Pacific. EKF Diagnostics Holdings PLC was formed in 2010 through the merger of three diagnostic companies. The history of EKF Diagnostics Holdings PLC began in 1990 with the founding of Hemocontrol. This company developed innovative devices for monitoring blood coagulation in patients with red blood cell abnormalities. In 1995, Dade Behring Diagnostics (DBD) was established as a subsidiary of Hemocontrol, specializing in the manufacture and marketing of diagnostic products. DBD quickly became a major player in the global diagnostics market and was acquired by Siemens in 2006. In 2001, Pointe Scientific was founded, a company focused on the development and production of high-quality diagnostic tests and instruments. The current business model of EKF Diagnostics Holdings PLC is based on four key areas: Diabetes Care, Point-of-Care, Central Lab, and Life Sciences. All four areas aim to develop and offer innovative solutions for better patient care. The Diabetes Care segment offers diagnostic products for monitoring diabetes. It includes HemoScan, a device for measuring hemoglobin A1C, a test that measures blood sugar levels over several months, enabling the diagnosis and monitoring of diabetes. The Point-of-Care segment offers tests and devices for performing diagnoses and treatments directly at the point of care. This includes devices for measuring blood sugar and cholesterol, as well as devices for determining hemoglobin or troponin. The Central Lab segment offers a wide range of diagnostic tests and instruments for determining blood chemistry, hematology, and immunology. This includes autoanalyzers, hemoglobin counters, and blood glucose meters. The Life Sciences segment offers a wide range of diagnostic tests, instruments, and reagents. This includes tests for cancer diagnosis and monitoring thyroid function. The company offers a variety of products to ensure optimal patient care. This includes diagnostic tests for determining infectious diseases or monitoring chronic conditions. EKF Diagnostics Holdings PLC is a company that is constantly evolving and strives to offer innovative products and solutions. The company places great emphasis on research and development to stay at the forefront of the changing market. The company has an experienced team of technicians and scientists dedicated to the development, production, and marketing of diagnostic products. EKF Diagnostics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding EKF Diagnostics Holdings's Return on Equity (ROE)

EKF Diagnostics Holdings's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing EKF Diagnostics Holdings's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

EKF Diagnostics Holdings's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in EKF Diagnostics Holdings’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about EKF Diagnostics Holdings stock

What is the ROE (Return on Equity) of EKF Diagnostics Holdings this year?

The ROE of EKF Diagnostics Holdings this year is 0.04 undefined.

How has the Return on Equity (ROE) of EKF Diagnostics Holdings developed compared to the previous year?

The ROE of EKF Diagnostics Holdings has increased by -125.45% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of EKF Diagnostics Holdings?

A high ROE indicates that EKF Diagnostics Holdings generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of EKF Diagnostics Holdings?

A low ROE can indicate that EKF Diagnostics Holdings is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of EKF Diagnostics Holdings affect the company?

A change in ROE (Return on Equity) of EKF Diagnostics Holdings can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of EKF Diagnostics Holdings?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of EKF Diagnostics Holdings?

Some factors that can influence EKF Diagnostics Holdings's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does EKF Diagnostics Holdings pay?

Over the past 12 months, EKF Diagnostics Holdings paid a dividend of 0.01 GBP . This corresponds to a dividend yield of about 4.44 %. For the coming 12 months, EKF Diagnostics Holdings is expected to pay a dividend of 0.01 GBP.

What is the dividend yield of EKF Diagnostics Holdings?

The current dividend yield of EKF Diagnostics Holdings is 4.44 %.

When does EKF Diagnostics Holdings pay dividends?

EKF Diagnostics Holdings pays a quarterly dividend. This is distributed in the months of December, December, December, December.

How secure is the dividend of EKF Diagnostics Holdings?

EKF Diagnostics Holdings paid dividends every year for the past 7 years.

What is the dividend of EKF Diagnostics Holdings?

For the upcoming 12 months, dividends amounting to 0.01 GBP are expected. This corresponds to a dividend yield of 4.05 %.

In which sector is EKF Diagnostics Holdings located?

EKF Diagnostics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von EKF Diagnostics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EKF Diagnostics Holdings from 12/1/2023 amounting to 0.012 GBP, you needed to have the stock in your portfolio before the ex-date on 11/2/2023.

When did EKF Diagnostics Holdings pay the last dividend?

The last dividend was paid out on 12/1/2023.

What was the dividend of EKF Diagnostics Holdings in the year 2023?

In the year 2023, EKF Diagnostics Holdings distributed 0.012 GBP as dividends.

In which currency does EKF Diagnostics Holdings pay out the dividend?

The dividends of EKF Diagnostics Holdings are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EKF Diagnostics Holdings

Our stock analysis for EKF Diagnostics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EKF Diagnostics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.